A Study of Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing Setting

Part of paid clinical trials in Milwaukee, Wisconsin.

Sponsor
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Study ID
NCT06788639
Status
Recruiting
Apply to this trial

Conditions

  • Chronic Lymphocytic Leukemia (CLL)
  • Small Lymphocytic Lymphoma (SLL)

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Lisocabtagene maraleucel — BIOLOGICAL
    According to the United States Prescribing Information

Study Details

The purpose of this study is to characterize the long-term safety of lisocabtagene maraleucel (liso-cel), focusing on patients treated in the chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) indication, and will be part of post-marketing liso-cel pharmacovigilance activities

Key Dates

First listed
Jan 23, 2025
Start date
Feb 4, 2025
Status verified
Feb 2025
Primary completion
Jun 30, 2044
Completion
Jun 30, 2044

Study Design

Enrollment
300 participants (estimated)

Arms

  • Arm: Participants treated with lisocabtagene maraleucel

Primary Outcome Measure

Adverse events (AEs) [ Time Frame: Up to 15 years ]

Central Contacts

  • BMS Study Connect Contact Center www.BMSStudyConnect.com
    855-907-3286
    [email protected]
  • First line of the email MUST contain NCT # and Site #.

Locations (1)

FacilityCityStateZIPSite coordinators
Center for International Blood and Marrow Transplant Research (CIBMTR)MilwaukeeWisconsin53226-

Find similar trials in Milwaukee, WI

By research site
Center for International Blood and Marrow Transplant Research (CIBMTR)· Milwaukee, WI

Related Studies